Indacaterol/glycopyrronium bromide
 | |
| Combination of | |
|---|---|
| Indacaterol | Ultra-long-acting beta-adrenoceptor agonist |
| Glycopyrronium bromide | Muscarinic anticholinergic |
| Clinical data | |
| Trade names | Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler |
| Pregnancy category |
|
| Routes of administration | Inhalation only |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:
- Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA);[1]
- Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.
Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[2]
The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[2][3] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.[4]
References
- ↑ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. S2CID 11930383.
- 1 2 "Ultibro Breezhaler". medicines.org.uk. DataPharm. 3 February 2015. Retrieved 9 February 2015.
- ↑ "Approval History: NDA 207930". DRUGS@FDA. US FDA. Retrieved 14 May 2016.
- ↑ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.
External links
- "Glycopyrrolate mixture with indacaterol". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.